´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ KGOG 2021 Semi-Annual Meeting : 2021-05-15±³À°ÀÏÀÚ : 2021-05-15
±³À°Àå¼Ò : ºí·ëºñ½ºÅ¸ ¾çÆò
±³À°ÁÖÁ¦ :
KGOG 2021 Semi-Annual MeetingÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5444
À̸ÞÀÏ :
koreagynonco@hanmail.net ±³À°Á¾·ù : »êºÎÀΰú
Âü¼®¿¹»óÀοø : 99¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
°æ±âµµ±³À°½Ã°£ : 8 ½Ã°£ 56ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:00~08:15 Lesson model society NRG corpus: What is missing in KGOG? Matthew A. Powell(NRG Uterine Corpus Committee Chair)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:15~08:30 Reasonable choice of target treatment among HER2(+) uterine cancer patients Amanda Nickles Fader(Johns Hopkins Hospital)
Åä·Ð 05-15 ±×·£µåº¼·ë 08:30~08:36 Discussion ()
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:36~08:39 Review of ongoing study- KGOG 2020: EM cancer, Fertility sparing high dose oral progestin ¿Ü ¹ÚÁ¤¿(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:39~08:42 Review of ongoing study-KGOG 2021 : TREE PRO ±è±âµ¿(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:42~08:45 Review of ongoing study-KGOG 2022 (NRG-GY018) ±è¹ýÁ¾(¿øÀڷº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:45~08:48 Review of ongoing study-KGOG 2023 À̹æÇö(ÀÎÇϴ뺴¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:48~08:51 Review of ongoing study-KGOG 2024 : Phase II CR-GTP, pembroizumab ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:51~08:54 Review of ongoing study-KGOG 2025 (AtEND) ÀÌö¹Î(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:54~08:57 Review of ongoing study-KGOG 2026: RACHEL PRO ±è±âµ¿(ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 08:57~09:00 Review of ongoing study-KGOG 2027 (NRG-GY020) ¹ÚÁ¤¿(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:00~09:03 Review of ongoing study-KGOG 2028 : Radiation Oncology & GYN oncology patterns of survey ±è¹Î±Ô(â¿ø»ï¼ºº´¿ø)
Åä·Ð 05-15 ±×·£µåº¼·ë 09:03~09:08 Discussion ()
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:08~09:18 Proposal of new concepts- A. Sentinel lymph node (SNL) mapping for endometrial cancer ¹ÚÁ¤¿(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 09:18~09:28 Proposal of new concepts- Endometrial cancer screening of hysteroscopy with dye (Chromo- Hysteroscopy) in high-risk population (HysteroLynch ) ±è¹Î±Ô(â¿ø»ï¼ºº´¿ø)
±âŸ 05-15 ±×·£µåº¼·ë 09:28~09:30 Closing ()
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 10:30~10:33 Cervix-Intorudction À̱ÙÈ£(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 10:33~11:03 Review of ongoing study-KGOG 1028, 1036, 1037 Á¤¿ë¿í(°³²Â÷º´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:03~12:13 Proposal of new concepts A. Comparison of adjuvant radiotherapy versus observation in "intermediate risk" early cervical cancer patients after radical hysterectomy: Propensity score matching study ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:13~11:23 Proposal of new concepts Prediction model for survival and recurrence in early-stage cervical cancer patients with radical trachelectomy: A multicencer cohort study ±è´ë¿¬(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:23~11:33 Proposal of new concepts DEBULK- Therapeutic effect of surgical debulking of metastatic LNs in cervical cancer stage IIIC before CCRT ³ëÁÖ¿ø(ÀÏ»êÂ÷º´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 11:33~11:43 Proposal of new concepts Real world data of sentinel lymph node dissection in gynecologic cancer ¼ÛÈñ°æ(¼¿ï¼º¸ðº´¿ø)
±âŸ 05-15 ±×·£µåº¼·ë 11:43~11:45 Closing ±è»ó¿î(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 13:00~13:25 Niraparib in patients with newly diagnonsed advanced ovarian cancer : PRIMA trial ±èÈñ½Â(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 13:25~13:50 Updated data of niraparib in Aasian patient ¼ÛÇϳª(°æ»ó´ëº´¿ø)
Åä·Ð 05-15 ±×·£µåº¼·ë 13:50~14:00 Discussion ()
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:00~14:08 Ovary-Introduction ÃÖÇöÁø(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:08~14:13 Study Review of OV TSC-KGOG 3035(JGOG3020) À̼ºÁ¾(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:13~14:18 Study Review of OV TSC-KGOG 3039(SUNNY): Sunny and Trust ±èÀç¿ø(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:18~14:23 Study Review of OV TSC-KGOG 3042 IDSHIPEC: Current status of HIPEC in the GYN ONC community Àå¼®ÁØ(¾ÆÁִ뺴¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:23~14:38 Study Review of OV TSC-KGOG 3045 AMBITION/3025 TRU-D : "From small Phase to pivotal study" ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:38~14:43 Study Review of OV TSC-KGOG 3047 somatic mutational landscape of epithelial ovarian carcinoma and its clinical implications targeted next-generation sequencing: A multi-center study ÀÌÁ¤¿ø(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:43~14:48 Study Review of OV TSC-KGOG 3048: Progress of KGOG 3048 ÃÖ¹Îö(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:48~15:53 Study Review of OV TSC-KGOG 3049 À̹æÇö(ÀÎÇϴ뺴¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:53~14:58 Study Review of OV TSC-KGOG 3051(NRG-GY019): Management of low grade serous ovarian cancer ÀÌÀ¯¿µ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 14:58~15:03 Study Review of OV TSC-KGOG 3053 (NRG-CC008) ÃÖÇöÁø(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:03~15:08 Study Review of OV TSC-KGOG 3056: A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive ovarian cancer patients previously treated with a PAR inhibitor (Nirvana-R) ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:08~15:18 Proposal of new concepts A. KGOG 3058: Effectiveness and safety of PARP-inhibitor maintenance therapy in recurrent ovarian cancer patients in real world Retrospective cohort study(ESPOIR) ÃÖÇöÁø(Á߾Ӵ뺴¿ø)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 15:18~15:28 Proposal of new concepts-OV 1908: A Phase I Clinical Trial of the Azacitidine(Azalid¢ç) with the Paclitaxel Polymeric Micelle (Genexol¢ç PM) in the treatment of patients with advanced or metastatic ovarian cancer À̽ÅÈ(¼¿ï¾Æ»êº´¿ø)
±âŸ 05-15 ±×·£µåº¼·ë 15:28~15:30 Closing °¼®¹ü(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 16:30~16:55 Clinical development of PARPi in ovarian cancer (past and future) and development of biomarkers of PARPi and HRD pathway Richard Davidson(UK)
±³À°½Ã°£ 05-15 ±×·£µåº¼·ë 16:55~17:20 Optimal front-line treatment with precision medicine in advanced ovarian cancer ÀÌÀ¯¿µ(»ï¼º¼¿ïº´¿ø)
Åä·Ð 05-15 ±×·£µåº¼·ë 17:20~17:30 Discussion ()
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:00~12:03 Rare tumor-Introduction ÃÖöÈÆ(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:03~12:23 Mucinous carcinoma of GYN origin (intraepithelial mucinous carcinoma of ovary, gastric type cervical adenocarcinoma) ±è±Ô·¡(¼¿ï¾Æ»êº´¿ø º´¸®°ú)
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:23~12:31 MIS vs. open surgery in rare histology cervical cancer ±è¼¼ÀÍ(¼¿ï´ëº´¿ø)
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:31~12:39 A MRI based machine learning approach for distinguishing uterine sarcoma from leiomyomas ±èÅÂÈÆ(º¸¶ó¸Åº´¿ø)
±³À°½Ã°£ 05-15 Room B, C-302 È£ 12:39~12:47 Radical vs. fertility sparing surgery in intraepithelial mucinous carcinoma of ovary ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±âŸ 05-15 Room B, C-302 È£ 12:47~12:49 Closing ÃÖöÈÆ(»ï¼º¼¿ïº´¿ø)